Moderna, Inc. MRNA SPX
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
READ MORE ›Market & Price
Valuation
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Growth (CAGR)
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Revenue declined at -53.3% CAGR over 5 years.
- Earnings shrank at -44.6% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | MRNA Moderna, Inc. SPX | 47.19 | - | $18.72B | - | -26.64% | -36.56% | -53.30% | -44.58% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Quarterly Results
Figures in USD.
| Metric | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | 16.02M | 13.08M | 17.05M | - | - | - | - | - | - | - | - | - | 3.36B | 1.86B | 344.00M | 1.83B | 167.00M | 241.00M | 1.86B | - | 107.00M | 137.00M | 1.00B | 676.00M | 389.00M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 90.00M | 119.00M | 207.00M | 452.00M | 955.00M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 17.00M | 18.00M | 795.00M | 224.00M | -566.00M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.07B | 925.00M | 1.05B | 1.08B | 822.00M |
| Operating Income | -65.46M | -94.19M | -67.87M | -41.83M | -77.40M | -97.02M | -85.82M | -153.03M | -141.64M | -143.71M | -130.76M | -130.56M | -131.00M | -122.00M | -235.00M | 1.27B | 3.06B | 3.56B | 4.23B | 2.45B | 1.17B | -366.00M | -1.87B | -2.01B | -1.27B | -1.36B | -70.00M | - | -1.05B | -907.00M | -260.00M | -857.00M | -1.39B |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -924.00M | -760.00M | -135.00M | -724.00M | -1.26B |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.00M | 1.00M | 0 | 8.00M | 17.00M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -964.00M | -818.00M | -187.00M | -799.00M | -1.33B |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 7.00M | 7.00M | 13.00M | 27.00M | 9.00M |
| Net Income | - | - | - | - | -72.38M | -90.60M | -80.33M | - | -132.58M | -134.94M | -123.22M | - | -124.00M | -117.00M | -233.00M | 1.22B | 2.78B | 3.33B | 3.66B | 2.20B | 1.04B | 79.00M | -1.38B | -3.63B | -1.18B | -1.28B | 13.00M | - | -971.00M | -825.00M | -200.00M | -826.00M | -1.34B |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | -0.35 | -0.31 | -0.59 | 2.84 | 6.46 | 7.70 | 8.58 | 5.24 | 2.53 | 0.19 | -3.62 | -9.53 | -3.07 | -3.33 | 0.03 | - | -2.52 | -2.13 | -0.51 | -2.11 | -3.40 |
| R&D Expense | - | - | - | - | 90.12M | 104.48M | 109.05M | - | 130.41M | 128.31M | 119.64M | - | 115.00M | 152.00M | 344.00M | 401.00M | 421.00M | 521.00M | 554.00M | 710.00M | 820.00M | 1.13B | 1.15B | 1.16B | 1.06B | 1.22B | 1.14B | - | 856.00M | 700.00M | 801.00M | - | 649.00M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | 60.21M | - | - | 18.88B | 6.75B | 3.20B | 1.92B |
| Cost of Revenue | - | - | - | - | - | - | 5.42B | 4.69B | 1.46B | 868.00M |
| Gross Profit | - | - | - | - | - | - | 13.46B | 2.06B | 1.74B | 1.05B |
| Operating Expenses | - | - | - | - | - | - | 4.04B | 6.30B | 5.68B | 4.13B |
| Operating Income | -223.77M | -269.36M | -413.27M | -546.00M | -763.00M | - | 9.42B | -4.24B | -3.94B | -3.07B |
| EBITDA | - | - | - | - | - | - | 9.77B | -3.62B | -3.39B | -2.54B |
| Interest Expense | - | - | - | - | - | - | 29.00M | 38.00M | 24.00M | 10.00M |
| Pretax Income | - | - | - | - | - | - | 9.57B | -3.94B | -3.61B | -2.77B |
| Tax Provision | - | - | - | - | - | - | 1.21B | 772.00M | -46.00M | 54.00M |
| Net Income | -216.21M | -255.92M | -384.73M | -514.00M | -747.00M | - | 8.36B | -4.71B | -3.56B | -2.82B |
| Diluted EPS | - | - | - | -1.55 | -1.96 | 28.29 | 20.12 | -12.33 | -9.28 | - |
| R&D Expense | 274.72M | 410.46M | 454.08M | 496.00M | 1.37B | 1.99B | 3.29B | 4.84B | 4.54B | 3.13B |
Compounded Sales Growth
| 5 Years: | -53.30% |
| 1 Year: | 260.20% |
Compounded Profit Growth
| 5 Years: | -44.58% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +77.67% |
| 6 Months: | +90.67% |
| 3 Months: | -11.91% |
| 1 Month: | +3.22% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Jan 2019 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 1.08B | 1.96B | 2.02B | 1.59B | 7.34B | - | 25.86B | 18.43B | 14.14B | 12.34B |
| Current Assets | - | - | - | - | - | - | - | - | 13.43B | 10.32B | 8.10B | 6.54B |
| Cash & Equivalents | 159.04M | 50.08M | 134.86M | 658.36M | - | 236.00M | 2.62B | - | 3.21B | 2.91B | 1.93B | 2.60B |
| Inventory | - | - | - | - | - | - | - | - | 949.00M | 202.00M | 117.00M | 153.00M |
| Receivables | - | - | - | - | - | - | - | - | 1.39B | 892.00M | 358.00M | 184.00M |
| Total Liabilities | - | - | 459.19M | 431.91M | - | 414.61M | 4.78B | - | 6.74B | 4.57B | 3.24B | 3.69B |
| Current Liabilities | - | - | 191.46M | 222.80M | - | 143.12M | 4.39B | - | 4.92B | 3.02B | 2.21B | 1.99B |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | 590.00M |
| Total Debt | - | - | - | - | - | - | - | - | 1.20B | 1.24B | 747.00M | 1.30B |
| Total Equity | -149.76M | -334.81M | -551.37M | 1.53B | - | 1.18B | 2.56B | - | 19.12B | 13.85B | 10.90B | 8.65B |
| Shares Outstanding | - | - | - | - | - | - | - | - | 385.00M | 382.00M | 386.00M | 394.00M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 66.73M | -331.48M | -330.87M | -459.00M | 2.03B | - | 4.98B | -3.12B | -3.00B | -1.87B |
| Investing Cash Flow | -648.61M | 417.36M | -373.09M | -15.00M | -1.67B | - | -5.18B | 4.21B | 1.95B | 1.95B |
| Financing Cash Flow | 472.91M | 168.00K | 1.23B | 52.00M | 2.03B | - | -3.45B | -1.38B | 56.00M | 593.00M |
| Capital Expenditure | -33.14M | -58.40M | -105.77M | -32.00M | -68.00M | - | -400.00M | -707.00M | -1.05B | -202.00M |
| Free Cash Flow | 33.59M | -389.88M | -436.63M | -491.00M | 1.96B | - | 4.58B | -3.83B | -4.05B | -2.08B |
| Net Change in Cash | - | - | - | - | - | - | -3.64B | -289.00M | -999.00M | 666.00M |
| Share Buybacks | - | - | - | 0 | 0 | 857.00M | 3.33B | 1.15B | 0 | 2.00M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | 71.3% | 30.5% | 54.2% | 54.8% |
| Operating Margin % | - | - | - | -906.8% | - | - | 49.9% | -62.8% | -123.3% | -159.9% |
| Net Margin % | - | - | - | -853.7% | - | - | 44.3% | -69.8% | -111.3% | -146.8% |
| ROE % | 64.6% | 46.4% | -25.1% | -43.7% | -29.2% | - | 43.7% | -34.0% | -32.7% | -32.6% |
| ROCE % | - | -30.2% | -23.8% | -37.8% | -25.9% | - | 45.0% | -27.5% | -33.1% | -29.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | FMR, LLC | 11.51% | 45.67M | $2.16B |
| 2 | Blackrock Inc. | 7.47% | 29.64M | $1.40B |
| 3 | Vanguard Capital Management LLC | 5.76% | 22.87M | $1.08B |
| 4 | BAILLIE GIFFORD & CO | 5.04% | 19.99M | $943.13M |
| 5 | Capital World Investors | 4.71% | 18.70M | $882.34M |
| 6 | Vanguard Portfolio Management LLC | 3.94% | 15.62M | $736.94M |
| 7 | State Street Corporation | 3.75% | 14.86M | $701.31M |
| 8 | Geode Capital Management, LLC | 2.38% | 9.44M | $445.24M |
| 9 | Two Sigma Investments, LP | 2.29% | 9.09M | $428.79M |
| 10 | Morgan Stanley | 2.13% | 8.47M | $399.76M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for MRNA